A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma

The purpose of this study is to determine the optimal dose of AGEN2373 that is safe when given in combination with balstilimab and Pancreatic GVAX Whole Cell Vaccine and evaluate the safety and clinical activity of balstilimab and AGEN2373 in combination with GVAX (Arm 1) or mKRASvax (Arm 2) in surgically resectable pancreatic adenocarcinoma.

Start Date01 Jun 2025

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+3]

NCT03767582

/ CompletedPhase 1/2IIT

A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs).

The purpose of this study is to evaluate if the combination of nivolumab and a CCR2/CCR5 dual antagonist (BMS-813160) with GVAX is safe in patients with locally advanced pancreatic cancer (LAPC) who have received chemotherapy and radiotherapy, and to see if this combination therapy enhances the infiltration of CD8+CD137+ cells in PDACs .

Start Date12 Dec 2019

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+1]

NCT03153410

/ CompletedEarly Phase 1IIT

A Pilot Study of a GVAX Pancreas Vaccine (With Cyclophosphamide) in Combination With a PD-1 Blockade Antibody (Pembrolizumab) and a Macrophage Targeting Agent (CSF1R Inhibitor) for the Treatment of Patients With Borderline Resectable Adenocarcinoma of the Pancreas

The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.

Start Date27 Sep 2018

Sponsor / Collaborator

The Sidney Kimmel Comprehensive Cancer Center

[+2]

100 Clinical Results associated with Enistimagene Setitucel/Damistimagene Matitucel

100 Translational Medicine associated with Enistimagene Setitucel/Damistimagene Matitucel

100 Patents (Medical) associated with Enistimagene Setitucel/Damistimagene Matitucel

Literatures (Medical) associated with Enistimagene Setitucel/Damistimagene Matitucel

01 Dec 2019·Journal for immunotherapy of cancerQ2 · MEDICINE

Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies

Q2 · MEDICINE

ArticleOA

Author: Foley, Kelly ; Armstrong, Todd D ; Xia, Tao ; Kim, Victoria M ; Che, Xu ; Blair, Alex B ; Wolfgang, Christopher L ; Jaffee, Elizabeth M ; Zheng, Lei ; Soares, Kevin ; Muth, Stephen T ; Brockstedt, Dirk ; Kleponis, Jennifer ; Lauer, Peter

BACKGROUND:

Immune checkpoint inhibitors are not effective for pancreatic ductal adenocarcinoma (PDAC) as single agents. Vaccine therapy may sensitize PDACs to checkpoint inhibitor treatments. Annexin A2 (ANXA2) is a pro-metastasis protein, previously identified as a relevant PDAC antigen that is expressed by a GM-CSF-secreting allogenic whole pancreatic tumor cell vaccine (GVAX) to induce an anti-ANXA2 antibody response in patients with PDAC. We hypothesized that an ANXA2-targeting vaccine approach not only provokes an immune response but also mounts anti-tumor effects.

METHODS:

We developed a Listeria-based, ANXA2-targeting cancer immunotherapy (Lm-ANXA2) and investigated its effectiveness within two murine models of PDAC.

RESULTS:

We show that Lm-ANXA2 prolonged the survival in a transplant model of mouse PDACs. More importantly, priming with the Lm-ANXA2 treatment prior to administration of anti-PD-1 antibodies increased cure rates in the implanted PDAC model and resulted in objective tumor responses and prolonged survival in the genetically engineered spontaneous PDAC model. In tumors treated with Lm-ANXA2 followed by anti-PD-1 antibody, the T cells specific to ANXA2 had significantly increased INFγ expression.

CONCLUSIONS:

For the first time, a listeria vaccine-based immunotherapy was shown to be able to induce a tumor antigen-specific T cell response within the tumor microenvironment of a "cold" tumor such as PDAC and sensitize the tumor to checkpoint inhibitor therapy. Moreover, this combination immunotherapy led to objective tumor responses and survival benefit in the mice with spontaneously developed PDAC tumors. Therefore, our study supports developing Lm-ANXA2 as a therapeutic agent in combination with anti-PD-1 antibody for PDAC treatment.

15 Sep 2019·Clinical cancer research : an official journal of the American Association for Cancer ResearchQ1 · MEDICINE

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Q1 · MEDICINE

Article

Author: Andrew H. Ko ; Elizabeth M. Jaffee ; Daniel A. Laheru ; Tony Reid ; Sandy Ferber ; Hedy Kindler ; Amanda Enstrom ; Nitya Nair ; Paul E. Oberstein ; Zev A. Wainberg ; Dung T. Le ; Michael A Morse ; Aimee Murphy ; Todd Crocenzi ; Vincent J Picozzi ; Noelle K. LoConte ; Herbert Zeh ; Erkut Borazanci ; Colin D. Weekes ; Dirk G Brockstedt ; Andrea Wang-Gillam ; Benjamin Musher ; Chan Whiting

Abstract:

Purpose::

Limited options exist for patients with advanced pancreatic cancer progressing after 1 or more lines of therapy. A phase II study in patients with previously treated metastatic pancreatic cancer showed that combining GVAX pancreas (granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreatic tumor cells) with cyclophosphamide (Cy) and CRS-207 (live, attenuated Listeria monocytogenes expressing mesothelin) resulted in median overall survival (OS) of 6.1 months, which compares favorably with historical OS achieved with chemotherapy. In the current study, we compared Cy/GVAX + CRS-207, CRS-207 alone, and standard chemotherapy in a three-arm, randomized, controlled phase IIb trial.

Patients and Methods::

Patients with previously treated metastatic pancreatic adenocarcinoma were randomized 1:1:1 to receive Cy/GVAX + CRS-207 (arm A), CRS-207 (arm B), or physician's choice of single-agent chemotherapy (arm C). The primary cohort included patients who had failed ≥2 prior lines of therapy, including gemcitabine. The primary objective compared OS between arms A and C in the primary cohort. The second-line cohort included patients who had received 1 prior line of therapy. Additional objectives included OS between all treatment arms, safety, and tumor responses.

Results::

The study did not meet its primary efficacy endpoint. At the final study analysis, median OS [95% confidence interval (CI)] in the primary cohort (N = 213) was 3.7 (2.9–5.3), 5.4 (4.2–6.4), and 4.6 (4.2–5.7) months in arms A, B, and C, respectively, showing no significant difference between arm A and arm C [P = not significant (NS), HR = 1.17; 95% CI, 0.84–1.64]. The most frequently reported adverse events in all treatment groups were chills, pyrexia, fatigue, and nausea. No treatment-related deaths occurred.

Conclusions::

The combination of Cy/GVAX + CRS-207 did not improve survival over chemotherapy. (ClinicalTrials.gov ID: NCT02004262)See related commentary by Salas-Benito et al., p. 5435

News (Medical) associated with Enistimagene Setitucel/Damistimagene Matitucel

30 Mar 2015

·www.biospace.com

Tiny Aduro Biotech Snags $750M Cancer Deal With Drug Giant Novartis AG

March 30, 2015 By Riley McDermid , BioSpace.com Breaking News Sr. Editor Scrappy Bay Area clinical stage cancer therapy company Aduro Biotech is celebrating Monday, after announcing drug behemoth Novartis AG will pay $200 million upfront to gain a 2.7 percent equity stake in Aduro for $25 million, the companies said. Under the terms of the deal, Novartis will also pour in another $25 million investment, with Aduro eligible for an extra $500 million in milestone payments. Novartis made the deal primarily to gain access to Aduro ’s promising STING (Stimulator of Interferon Genes) receptor technology. The deal will now give it the rights to the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro ’s cyclic dinucleotide (CDN) approach to target STING. “We are delighted to collaborate with Aduro . We believe this target is among the most exciting in oncology today, the drug candidate to be of the highest quality, and the talent of our new colleagues from Aduro to be fantastic,” said Novartis ’ Mark C. Fishman, M.D. , president of the Novartis Institutes for BioMedical Research . “We anticipate many clinical opportunities will be explored with the CDN approach, both directly and in combination with other agents.” Aduro has been riding high since January, after raking in $51.4 million in a Series D funding round from 11 investors including OrbiMed , Franklin Advisers , Foresite Capital Management , Clough Capital Partners , Janus Capital Management and Jennison Associates . Leerink Partners acted as bookrunners on the deal. Berkeley, Calif.-based Aduro said it will use the investment for to expand its research and clinical development capabilities, as it attempts to roll out its immuno-oncology platform in 2015. The company is best known for its experimental combo of proprietary drugs CRS-207 and GVAX Pancreas, a mix that is attracting investor interest as it goes through ECLIPSE, a 240 patient Phase 2b clinical trial to treat metastatic pancreatic cancer. The cocktail received a breakthrough therapy designation from the U.S. Food and Drug Administration (FDA) last year, a “golden ticket” which has investors circling around the company as it fast-tracks its drug program. The startup last received a $55 million Series C round from Morningside Group and Johnson & Johnson Development Corporation , bringing its total investment so far to $143.4 million. Aduro has been focusing on developing a platform of live-attenuated double-deleted Listeria monocytogenes strains (or LADD) that it has engineered to jumpstart an immune response in cancer patients. Its lead drug, CRS-207, works by expressing the tumor-associated antigen mesothelin, which makes it useful for treating mesothelioma and pancreatic, lung, ovarian and gastric cancers. “2014 was a watershed year for Aduro and this financing demonstrates investor confidence in our future,” said Stephen Isaacs , chairman, president and chief executive officer of Aduro . Aduro ’s other primary candidate is GVAX Pancreas, a drug that is a type of GVAX vaccines produced from human cancer cell lines and created to target T cells as a way to boost cancer immunity. Most of the company’s research is based on cyclic dinucleotides (CDNs), which are naturally occurring molecules that target an immunity regulator, dubbed the STING receptor. “Our accomplishments during the year, including demonstrating positive results in our pancreatic cancer and mesothelioma programs, receiving Breakthrough Therapy designation from the FDA for the combination of CRS-207 and GVAX Pancreas, and establishing two worldwide collaboration agreements with Johnson and Johnson Innovation ( Janssen Biotech Inc. ) for the development and commercialization of novel immunotherapies for prostate and lung cancers, have positioned us well to achieve our goal of providing patients with more effective and more tolerable alternatives to treat cancer,” he said. “ We look forward to completing enrollment in our Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer and further exploring the broad versatility and applicability of our LADD and CDN technologies in other cancers.” Last October Aduro inked a $30 million deal with the Johnson & Johnson Innovation Center in California to help it develop its nascent lung cancer therapies, the company announced Thursday. Under the terms of the pact, Janssen Biotech Inc. (JNJ) , part of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) , will receive an exclusive, worldwide license to several of the cancer drugs in Aduro ’s LADD immunotherapy platform Aduro received a $30 million up front and as much as $817 million as it hits development, regulatory and commercialization milestones payments. The company’s primary focus is experimental therapies using Listeria bacteria, which they genetically modify with disease-specific antigens. It had an earlier, existing partnership with Johnson & Johnson , but the larger company appears to be doubling down on the company as research evolves. Aduro lauded the agreement as a major step forward for the tiny biotech. The deal is still subject to clearance by American antitrust authorities under the Hart-Scott-Rodino Act . “Since our initial agreement with Janssen in May [2014] year for new immunotherapies for prostate cancer, they have been terrific partners and we’ve established a strong collaboration focused on advancing our technologies forward in their licensed indications,” said Isaacs at the time. Isaacs said Aduro continues to make progress with a broad array of immunotherapy platforms in a number of other oncology indications, including pancreatic cancer, mesothelioma and glioblastoma.

Phase 2License out/inVaccineImmunotherapyBreakthrough Therapy

26 Feb 2015

·www.biospace.com

Aduro Biotech Collaborates With Leaders In Cancer Research On Investigator-Sponsored Phase 2 Trial Combining Aduro’s Innovative Immunotherapies With Anti-PD-1 Technology To Treat Patients With Advanced Pancreatic Cancer

- Combination Immunotherapeutic Regimen Designed to Enhance Cancer Fighting Competency of Immune Cells - BERKELEY, Calif.--(BUSINESS WIRE)--Aduro Biotech, Inc. today announced the initiation of an investigator-sponsored Phase 2 clinical trial of the company’s immuno-oncology product candidates GVAX Pancreas and CRS-207 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab), a monoclonal antibody against programmed death-1 receptor (PD-1). The first patient has been enrolled in the trial that will be conducted at up to five U.S. clinical trial sites. “For some time, we have recognized and embraced the power of combination strategies for immuno-oncology and this trial will evaluate expanding our lead combination to include Opdivo, the first-in-class anti-PD-1” GVAX Pancreas and CRS-207 are designed to stimulate an immune response against a tumor, and nivolumab is designed to remove an immuno-suppressive mechanism that cancer cells have developed against the immune system. Aduro believes the combination of CRS-207 and GVAX Pancreas with nivolumab may improve clinical outcomes because of their complementary mechanisms of action. The randomized, controlled STELLAR trial (Safety and Therapeutic Efficacy of Live-attenuated Listeria/GVAX with Anti-PD1 Regimen) will enroll approximately 88 adults with metastatic pancreatic cancer who have had one prior chemotherapy regimen for metastatic disease. The trial will include two arms: Arm A with CRS-207/GVAX Pancreas vaccine and nivolumab and Arm B with CRS-207/GVAX Pancreas vaccine. The primary objective of this study is to compare the overall survival (OS) of patients in Arm A and Arm B. Secondary endpoints include evaluation of clinical and immune response and safety. For more information, please visit ClinicalTrials.gov (Identifier: NCT02243371). The trial is supported by Stand up to Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research; Pancreatic Cancer Action Network – AACR Research Acceleration Network Grant, supported by Fredman Family Foundation; and Bristol-Myers Squibb. SU2C is a program of the Entertainment Industry Foundation. “For some time, we have recognized and embraced the power of combination strategies for immuno-oncology and this trial will evaluate expanding our lead combination to include Opdivo, the first-in-class anti-PD-1,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro. “While we continue our efforts to evaluate GVAX Pancreas and CRS-207 in our Phase 2b ECLIPSE trial as an effective treatment for pancreatic cancer, we look forward to generating data in yet another combination for potential future applications of our technologies.” “The Pancreatic Cancer Action Network is thrilled to have provided initial funding that has been leveraged for this important program,” said Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network. “In an effort to double pancreatic cancer survival by 2020, we are investing in projects that have the potential to improve the treatment landscape of pancreatic cancer and ultimately increase survival.” “Stand Up To Cancer is excited not only that this immunotherapy clinical trial has begun patient enrollment, one of the 120 clinical trials we have launched or completed,” stated SU2C President and CEO Sung Poblete, R.N, Ph.D., “but that it involves collaboration by two distinct biotechnology firms to study the combination of two proprietary immunotherapies. Stand Up To Cancer is proud to have facilitated this level of multi-institutional and corporate collaboration, which is at the core of SU2C’s research model and its mission to benefit cancer patients faster.” Last year, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Aduro’s pancreatic cancer combination treatment consisting of CRS-207 and GVAX Pancreas. According to the FDA, a Breakthrough Therapy designation is for a drug candidate that treats a serious or life-threatening condition and for which preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint over available therapies. Separately, Aduro is currently conducting a 240 patient Phase 2b clinical trial (ECLIPSE; identifier NCT02004262) in metastatic pancreatic cancer patients who have received at least one line of therapy. The randomized, controlled 3-arm trial will involve approximately 20 clinical trial sites in the United States and Canada and will evaluate the safety, immune response and efficacy of the combination immunotherapy of GVAX Pancreas in combination with CRS-207 compared to chemotherapy or to CRS-207 as a monotherapy. The primary endpoint of the trial is overall survival. About CRS-207 CRS-207 is one of a family of product candidates based on Aduro’s live-attenuated, double-deleted (LADD) Listeria monocytogenes immuno-oncology platform that are designed to induce potent innate and adaptive immune responses. CRS-207 has been engineered to express the tumor-associated antigen mesothelin, which is over-expressed in many cancers including mesothelioma and pancreatic, non-small cell lung, ovarian and gastric cancers. About GVAX Pancreas GVAX Pancreas is one of a family of GVAX vaccines derived from human cancer cell lines that are genetically modified to express granulocyte-macrophage colony-stimulating factor (GM-CSF), an immune system-stimulating cytokine. GVAX Pancreas is derived from human pancreatic cancer cell lines and is designed to activate specific T cell immunity to pancreatic cancer antigens, including mesothelin. About the Stand Up To Cancer Initiative Stand Up To Cancer (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a program of the Entertainment Industry Foundation (EIF), a 501(c)(3) charitable organization, was established in 2008 by film and media leaders who utilize the industry’s resources to engage the public in supporting a new, collaborative model of cancer research, and to increase awareness about cancer prevention as well as progress being made in the fight against the disease. As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee led by Nobel Laureate Phillip A. Sharp, PhD, conduct rigorous, competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and provide expert review of research progress. About the Pancreatic Cancer Action Network The Pancreatic Cancer Action Network is the national organization creating hope in a comprehensive way through research, patient support, community outreach and advocacy for a cure. The organization is leading the way to increase survival for people diagnosed with this devastating disease through a bold initiative — The Vision of Progress: Double Pancreatic Cancer Survival by 2020. Together, we can Wage Hope in the fight against pancreatic cancer by intensifying our efforts to heighten awareness, raise funds for comprehensive private research, and advocate for dedicated federal research to advance early diagnostics and better treatments and increase chances of survival. For more information, go to . About Aduro Aduro Biotech, Inc. is a private, clinical-stage immuno-oncology company focused on the development of technology platforms to stimulate an immune response against cancer. Aduro’s lead platform is based on proprietary strains of live-attenuated, double-deleted (LADD) Listeria monocytogenes that induce a potent innate immune response and have been engineered to express tumor-associated antigens to induce tumor-specific T cell-mediated immunity. Aduro has received Breakthrough Therapy designation from the FDA for its lead LADD regimen, CRS-207 in combination with GVAX Pancreas in pancreatic cancer. The company is evaluating the proprietary immuno-oncology combination in the ongoing Phase 2b ECLIPSE clinical trial and has additional ongoing clinical trials with its LADD platform in mesothelioma and glioblastoma. The company is also developing clinical candidates using synthetic small molecule immune modulators that are designed to activate the intracellular STING receptor, a central mediator of the innate immune response. For more information, please visit . Contacts Aduro Biotech, Inc.Sylvia Wheeler, 510-809-9264SVP, Corporate AffairsorMedia Contact:Angela Bitting, 925-202-6211a.bitting@comcast.net Help employers find you! Check out all the jobs and post your resume.

VaccineCollaborateAntibodyBreakthrough TherapyFirst in Class

100 Deals associated with Enistimagene Setitucel/Damistimagene Matitucel

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Locally Advanced Pancreatic Adenocarcinoma	Phase 2	United States	The Sidney Kimmel Comprehensive Cancer Center	18 Jul 2016
Adenocarcinoma	Phase 2	United States	Aduro BioTech, Inc.	02 Jan 2015
Metastatic Pancreatic Cancer	Phase 2	United States	Aduro BioTech, Inc.	21 Sep 2011
Pancreatic adenocarcinoma metastatic	Phase 2	United States	Aduro BioTech, Inc.	21 Sep 2011
Advanced Pancreatic Adenocarcinoma	Phase 2	United States	The Sidney Kimmel Comprehensive Cancer Center	01 Dec 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03190265 (CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic	61	CRS-207+ipilimumab+Nivolumab	zjzpwruvsi = zodhoyogns yvefyidjlc (rjxuaxxipp, iathydtnap - dsigpbglca) View more	-	10 Jul 2023
NCT02648282 (CT134, CTgov)	Phase 2	Locally Advanced Pancreatic Adenocarcinoma	58	SBRT+Cyclophosphamide+pembrolizumab+GVAX Pancreatic Cancer Vaccine	jiskjfjdgh(xogcnsirxh) = mwfltbegkw dwlckadhud (wviigbdstu, rntwvoxwui - wgnznfvasv) View more	-	28 Feb 2023
NCT01896869 (CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Cancer	83	Ipilimumab (Ipilimumab + Vaccine)	wgocfffdmf(nebkxkcusn) = rgehsbwnnj uvgbeflbub (mvnnlycpzp, irdmfozmgm - lkrjwhharf) View more	-	06 May 2020
				FOLFIRINOX (FOLFIRINOX)	wgocfffdmf(nebkxkcusn) = dgewbbndml uvgbeflbub (mvnnlycpzp, rclsckrzar - tqwxzsgbvt) View more
NCT02243371 (CTgov)	Phase 2	Adenocarcinoma \| Pancreatic adenocarcinoma metastatic	93	CRS-207+nivolumab+CY+GVAX (Arm A: CY/ GVAX/ CRS-207/ Nivolumab)	znwytkfyca(joetpqodyz) = xvkogpbiiu mrxzhyxeuu (rcutzpolhw, aghyvmeljq - vhbhisqwyc) View more	-	08 Oct 2019
				CRS-207+CY+GVAX (Arm B: CY/ GVAX/ CRS-207)	znwytkfyca(joetpqodyz) = huewukbuxf mrxzhyxeuu (rcutzpolhw, znyqyvwlzc - gjminzwjgv) View more
NCT02004262 (ECLIPSE, Pubmed \| Clin Cancer Res)	Phase 2	Pancreatic adenocarcinoma metastatic	213	Cy/GVAX + CRS-207	yqmavvaluf(wcmfpmuxdy) = dluscsliyl twixyjujkw (fkjkprlhhg )	Negative	15 Sep 2019
				CRS-207	yqmavvaluf(wcmfpmuxdy) = oveqwwdkga twixyjujkw (fkjkprlhhg )
NCT01417000 (Phase IIa, CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Cancer	93	CRS-207+cyclophosphamide+GVAX Pancreas (Cy/GVAX + CRS-207)	xsicjfsguz(perfvombbl) = wkqtbjejlp bzctomnzcx (swwmhkbtng, xugxhukehn - xbnrozpdbe) View more	-	08 May 2018
				cyclophosphamide+GVAX Pancreas (Cy/GVAX)	xsicjfsguz(perfvombbl) = wpacwqgkgm bzctomnzcx (swwmhkbtng, gttxuafkgh - rteymppvye) View more
NCT02004262 (ECLIPSE, CTgov)	Phase 2	Pancreatic adenocarcinoma metastatic \| Metastatic Pancreatic Cancer	303	CRS-207+cyclophosphamide+GVAX Pancreas Vaccine (Primary Cohort: Cy/GVAX + CRS-207)	nrthyjacyj(lquudpttpx) = nlfnuewrvz xirfdtsggl (yyeckpfqxd, ooryeanayj - pqqislgsyl) View more	-	03 May 2018
				CRS-207 (Primary Cohort: CRS-207)	nrthyjacyj(lquudpttpx) = spwyzravpd xirfdtsggl (yyeckpfqxd, uyuypiscbx - svzvqvmbgy) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Enistimagene Setitucel/Damistimagene Matitucel

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation